Current Issue

View Larger Image

Past Issues Adlink Subscription Visit Our Publisher

Top Keywords

GEN podcasts

*Podcasts play in a pop-up window. Please make sure your pop-up blocker is off.

GEN’s editor in chief, John Sterling, interviews life science academic and biotech industry leaders on important research, technology, and trends. These podcasts will keep you informed with all the important details you need.

ROUNDTABLE DISCUSSION ON BIOTECH/PHARMA DEALS

9/25/2008

- Martina Molsbergen, VP, Business Development, Crucell; Barbara Yanni, Chief Licensing Officer, Merck & Co.; David Colpman, Senior VP, Business Development, Shire Pharmaceuticals; and Joern-Peter Halle, Head, Early-Stage Licensing, Merck Serono, a division of Merck KGaA

KEYWORDS:
Financing
,
M&A

In the Wall Street Biobeat column of the September 1st issue of GEN, Robert Dellenbach wrote that significant changes in the global economy and in the venture capital community have dramatically impacted the life sciences industry. What's more, his article appeared even before last month's near Wall Street meltdown. What's a biotech company to do for money?

GEN held a roundtable discussion with several industry professionals to find out. We discovered that dealmaking with pharma firms was on a dramatic upswing, and not just due to a lack of VC funding. The panel answered questions such as: What's driving the recent spate of deals, especially all the M&A and partnering activities between pharmaceutical companies and biotech firms? What does a pharma firm look for in a biotech company before entering such deals? What does a biotech company need to do to get the attention of a large pharmaceutical company? Does it seem like deals, and not drug products themselves or specific technologies, are now the main driving force behind the bio industry's growth?

Anyone involved in the biotechnology industry will find this podcast extremely compelling and timely as the biopharmaceutical industry continues to search for new and creative avenues of financing!

Barbara Yanni is Chief Licensing Officer at Merck & Co.

David Colpman is Senior VP of Business Development at Shire Pharmaceuticals.

Joern-Peter Halle is Head of Early-Stage Licensing at Merck Serono, a division of Merck KGaA

Martina Molsbergen is VP of Business Development at Crucell.

Subscription center

GEN MAGAZINE
	Genetic Engineering & Biotechnology News (GEN) has retained its position as the most widely read biotechnology publication around the globe since its launch in 1981. Published 21 times a year and with additional exclusive editorial content online, GEN's unique news and technology focus includes the entire bioproduct life cycle from early-stage R&D, to applied research including omics, biomarkers, as well as diagnostics, to bioprocessing and commercialization. Subscribe

e-NEWSLETTERS
Add GEN to your Inbox! Subscribe today to our complimentary e-newsletters and stay abreast of the latest biotech news and trends. Click the magnifying glass icon next to a newsletter title to view a sample.
GEN Daily News Highlights - provides succinct and timely biotech news on the entire biotech field. GEN News Highlights of the Week - showcases the week's top biotech news. GEN Table of Contents (TOC) Alert - This alert provides a sneak peak at the latest issue of GEN. GEN Tech Focus - is published monthly to provide the latest advances in biotech's hottest topics. GEN Biotech Events - a weekly newsletter featuring webinars, meetings, and conferences. GEN New Products Watch - a monthly summary of products and services by tool providers. New product information and special offers from select biotech suppliers.
	All fields are required
Email
Confirm Email
First Name
Last Name
Organization
E-Alert Format


	Sign Up